PET/MR of pediatric bone tumors: what the radiologist needs to know.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35804163.
- Also identified by DOI 10.1007/s00256-022-04113-6 and PMC identifier 9826799.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Integrated 2-deoxy-2-[fluorine-18]fluoro-D-glucose (<sup>18</sup>F-FDG) positron emission tomography (PET)/magnetic resonance (MR) imaging can provide "one stop" local tumor and whole-body staging in one session, thereby streamlining imaging evaluations and avoiding duplicate anesthesia in young children. <sup>18</sup>F-FDG PET/MR scans have the benefit of lower radiation, superior soft tissue contrast, and increased patient convenience compared to <sup>18</sup>F-FDG PET/computerized tomography scans. This article reviews the <sup>18</sup>F-FDG PET/MR imaging technique, reporting requirements, and imaging characteristics of the most common pediatric bone tumors, including osteosarcoma, Ewing sarcoma, primary bone lymphoma, bone and bone marrow metastases, and Langerhans cell histiocytosis.
Medical subject headings
- Fluorodeoxyglucose F18
- Bone Neoplasms